Irene Becklund Sells 8,485 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 8,485 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $506,978.75. Following the completion of the transaction, the insider now directly owns 712 shares in the company, valued at $42,542. This trade represents a 92.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Irene Becklund also recently made the following trade(s):

• On Thursday, May 22nd, Irene Becklund sold 5,071 shares of Hims & Hers Health stock. The stock was sold at an average price of $53.51, for a total value of $271,349.21.
• On Tuesday, April 22nd, Irene Becklund sold 2,936 shares of Hims & Hers Health stock. The stock was sold at an average price of $26.49, for a total value of $77,774.64.
• On Thursday, April 3rd, Irene Becklund sold 2,203 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.78, for a total value of $63,402.34.

Hims & Hers Health Trading Down 1.0%

Shares of HIMS opened at $59.17 on Wednesday. The company’s 50 day simple moving average is $46.36 and its 200-day simple moving average is $38.60. The firm has a market cap of $13.24 billion, a PE ratio of 85.75, a price-to-earnings-growth ratio of 2.25 and a beta of 2.09. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm had revenue of $586.01 million during the quarter, compared to analysts’ expectations of $535.21 million. During the same quarter in the prior year, the business earned $0.05 EPS. Hims & Hers Health’s quarterly revenue was up 110.7% compared to the same quarter last year. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $38,000. Finally, UMB Bank n.a. lifted its holdings in shares of Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after purchasing an additional 933 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HIMS shares. Wall Street Zen upgraded Hims & Hers Health from a “hold” rating to a “buy” rating in a research note on Sunday. Piper Sandler reissued a “neutral” rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, June 4th. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Finally, TD Cowen downgraded shares of Hims & Hers Health from a “buy” rating to a “hold” rating and dropped their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.